Loading...
XTAETEVA
Market cap25bUSD
Dec 20, Last price  
7,712.00ILS
1D
1.88%
1Q
15.57%
Jan 2017
-44.24%
Name

Teva Pharmaceutical Industries Ltd

Chart & Performance

D1W1MN
XTAE:TEVA chart
P/E
—
P/S
151.60
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.85%
Rev. gr., 5y
-3.42%
Revenues
15.85b
+6.17%
4,798,900,0005,250,400,0008,408,000,0009,408,000,00011,085,000,00013,899,000,00016,121,000,00018,312,000,00020,317,000,00020,314,000,00020,272,000,00019,652,000,00021,903,000,00022,385,000,00018,854,000,00016,887,000,00016,658,000,00015,878,000,00014,925,000,00015,846,000,000
Net income
-559m
L-76.24%
331,800,0001,072,300,000546,000,0001,952,000,000635,000,0002,000,000,0003,331,000,0002,759,000,0001,963,000,0001,269,000,0003,055,000,0001,588,000,000329,000,000-16,265,000,000-2,150,000,000-999,000,000-3,990,000,000417,000,000-2,353,000,000-559,000,000
CFO
1.37b
-13.96%
1,248,800,0001,370,000,0002,058,000,0001,813,000,0003,231,000,0003,373,000,0004,136,000,0004,134,000,0004,572,000,0003,237,000,0005,127,000,0005,542,000,0005,225,000,0003,507,000,0002,446,000,000538,000,0001,216,000,000798,000,0001,590,000,0001,368,000,000
Dividend
Nov 28, 20178.5 ILS/sh
Earnings
Jan 29, 2025

Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
URL
https://www.tevapharm.com/
IPO date
Jan 01, 1951
Employees
34,004
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
15,846,000
6.17%
14,925,000
-6.00%
15,878,000
-4.68%
Cost of revenue
12,651,000
12,235,000
12,779,000
Unusual Expense (Income)
NOPBT
3,195,000
2,690,000
3,099,000
NOPBT Margin
20.16%
18.02%
19.52%
Operating Taxes
(7,000)
(638,000)
211,000
Tax Rate
6.81%
NOPAT
3,202,000
3,328,000
2,888,000
Net income
(559,000)
-76.24%
(2,353,000)
-664.27%
417,000
-110.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,672,000
2,109,000
1,426,000
Long-term debt
18,801,000
19,801,000
22,449,000
Deferred revenue
548,000
Other long-term liabilities
4,019,000
3,298,000
2,578,000
Net debt
17,239,000
19,109,000
21,710,000
Cash flow
Cash from operating activities
1,368,000
1,590,000
798,000
CAPEX
(526,000)
(548,000)
(562,000)
Cash from investing activities
968,000
656,000
1,523,000
Cash from financing activities
(1,913,000)
(1,487,000)
(2,172,000)
FCF
3,213,000
3,647,000
3,265,000
Balance
Cash
3,226,000
2,801,000
2,165,000
Long term investments
8,000
Excess cash
2,441,700
2,054,750
1,371,100
Stockholders' equity
(15,554,000)
(14,869,000)
(12,189,000)
Invested Capital
47,852,000
48,967,000
49,470,000
ROIC
6.61%
6.76%
5.69%
ROCE
9.71%
7.76%
8.14%
EV
Common stock shares outstanding
1,119,000
1,110,000
1,107,000
Price
10.44
14.47%
9.12
13.86%
8.01
-16.99%
Market cap
11,682,360
15.40%
10,123,200
14.17%
8,867,070
-16.09%
EV
29,541,360
30,026,200
31,543,070
EBITDA
4,348,000
3,998,000
4,429,000
EV/EBITDA
6.79
7.51
7.12
Interest
966,000
1,058,000
Interest/NOPBT
35.91%
34.14%